HC Wainwright & Co. Reiterates Buy on Mind Medicine, Maintains $75 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on Mind Medicine (NASDAQ:MNMD) and maintained a $75 price target.
June 28, 2023 | 5:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mind Medicine's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $75.
The reiteration of a 'Buy' rating and a maintained price target of $75 by HC Wainwright & Co. indicates a positive outlook for Mind Medicine. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100